Global Burden and Epidemiology of Tuberculosis

Clinics in Chest Medicine

Volumn 30, Issue 4, 2009, Pages 621-636

  Glaziou, Philippe ^a   Floyd, Katherine ^a   Raviglione, Mario ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Burden; Epidemiology; Incidence; Mortality; Prevalence; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; COTRIMOXAZOLE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC SENSITIVITY; ATTITUDE TO ILLNESS; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; CAUSE OF DEATH; CLINICAL TRIAL; COMMUNITY PROGRAM; DIAGNOSTIC TEST; DISEASE DURATION; DISEASE SEVERITY; DISEASE SURVEILLANCE; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MIXED INFECTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COUNSELING; PRACTICE GUIDELINE; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; RETREATMENT; REVIEW; SMEAR; SOCIOECONOMICS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

HUMANS; MORBIDITY; RISK ASSESSMENT; SURVIVAL RATE; TUBERCULOSIS; WORLD HEALTH;

EID: 71849108189     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2009.08.017     Document Type: Review

References (75)

1. In: WHO (Ed). The global burden of disease: 2004 update (2008), World Health Organization, Geneva 11-12
2. In: WHO (Ed). Global tuberculosis control 2009: surveillance, planning, financing (2009), World Health Organization, Geneva 1-303
3. Zumla A., Mwaba P., Huggett J., et al. Reflections on the white plague. Lancet Infect Dis 9 3 (2009) 197-202
4. Raviglione M.C., and Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 359 9308 (2002) 775-780
5. Murray C.J., DeJonghe E., Chum H.J., et al. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 338 8778 (1991) 1305-1308
6. Dye C., and Floyd K. Tuberculosis. In: Jamison D.T., Breman J.G., Measham A.R., et al. (Eds). Disease control priorities in developing countries (2006), Oxford University Press, Washington, DC 289-309
7. Wright A., Zignol M., Van Deun A., et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet 373 9678 (2009) 1861-1873
8. Dye C., Bassili A., Bierrenbach A.L., et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 8 4 (2008) 233-243
9. Raviglione M.C. The global plan to stop TB, 2006-2015. Int J Tuberc Lung Dis 10 3 (2006) 238-239
10. Raviglione M.C., and Uplekar M.W. WHO's new Stop TB Strategy. Lancet 367 9514 (2006) 952-955
11. Raviglione M.C. The new Stop TB Strategy and the Global Plan to Stop TB, 2006-2015. Bull World Health Organ 85 5 (2007) 327
12. World Health Organization. Global tuberculosis control: surveillance, planning, financing (2007), World Health Organization, Geneva
13. Dye C., Maher D., Weil D., et al. Targets for global tuberculosis control. Int J Tuberc Lung Dis 10 4 (2006) 460-462
14. Bierrenbach A.L., Stevens A.P., Gomes A.B., et al. [Impact on tuberculosis incidence rates of removal of repeat notification records]. Rev Saude Publica 41 Suppl 1 (2007) 67-76 [Portuguese]
15. Dye C., Ottmani S., Laasri L., et al. The decline of tuberculosis epidemics under chemotherapy: a case study in Morocco. Int J Tuberc Lung Dis 11 11 (2007) 1225-1231
16. Mansoer J., Floyd K., Dye C., et al. New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. Bull World Health Organ 87 (2009) 186-192
17. Dye C., Scheele S., Dolin P., et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282 7 (1999) 677-686
18. Botha E., den Boon S., Lawrence K.A., et al. From suspect to patient: tuberculosis diagnosis and treatment initiation in health facilities in South Africa. Int J Tuberc Lung Dis 12 8 (2008) 936-941
19. Uplekar M., Pathania V., and Raviglione M. Private practitioners and public health: weak links in tuberculosis control. Lancet 358 9285 (2001) 912-916
20. Meintjes G., Schoeman H., Morroni C., et al. Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis 8 (2008) 72
21. Veron L.J., Blanc L.J., Suchi M., et al. DOTS Expansion: will we reach the 2005 targets?. Int J Tuberc Lung Dis 8 1 (2004) 139-146
22. Baussano I., Bugiani M., Gregori D., et al. Undetected burden of tuberculosis in a low-prevalence area. Int J Tuberc Lung Dis 10 4 (2006) 415-421
23. Borgdorff M.W., Glynn J.R., and Vynnycky E. Using capture-recapture methods to study recent transmission of tuberculosis. Int J Epidemiol 33 4 (2004) 905-906 [author reply 7]
24. Cailhol J., Che D., Jarlier V., et al. Incidence of tuberculous meningitis in France, 2000: a capture-recapture analysis. Int J Tuberc Lung Dis 9 7 (2005) 803-808
25. Crofts J.P., Pebody R., Grant A., et al. Estimating tuberculosis case mortality in England and Wales, 2001-2002. Int J Tuberc Lung Dis 12 3 (2008) 308-313
26. Na Vanh, Story A., Grant A.D., et al. Record-linkage and capture-recapture analysis to estimate the incidence and completeness of reporting of tuberculosis in England 1999-2002. Epidemiol Infect 136 12 (2008) 1606-1616
27. Glaziou P., van der Werf M.J., Onozaki I., et al. Tuberculosis prevalence surveys: rationale and cost. Int J Tuberc Lung Dis 12 9 (2008) 1003-1008
28. In: WHO (Ed). Assessing tuberculosis prevalence through population-based surveys (2007), World Health Organization, Manila 1-235
29. Soemantri S., Senewe F.P., Tjandrarini D.H., et al. Three-fold reduction in the prevalence of tuberculosis over 25 years in Indonesia. Int J Tuberc Lung Dis 11 4 (2007) 398-404
30. Dye C., Fengzeng Z., Scheele S., et al. Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol 29 3 (2000) 558-564
31. Tupasi T.E., Radhakrishna S., Rivera A.B., et al. The 1997 nationwide tuberculosis prevalence survey in the Philippines. Int J Tuberc Lung Dis 3 6 (1999) 471-477
32. Hong Y.P., Kim S.J., Lew W.J., et al. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 2 (1998) 27-36
33. Korenromp E.L., Bierrenbach A.L., Williams B.G., et al. The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis 13 3 (2009) 283-303
34. Corbett E.L., Watt C.J., Walker N., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163 9 (2003) 1009-1021
35. UNAIDS. HIV epidemiology. Available at: (2009). http://www.unaids.org/en/KnowledgeCentre/HIVData/Epidemiology/latestEpiD ata.asp Accessed March 7, 2009
36. Shilova M.V., and Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond A 356 1411 (2001) 1069-1075
37. WHO. WHO and UNAIDS issue new guidance on HIV testing and counseling in health facilities. Available at: (2007). http://www.who.int/mediacentre/news/releases/2007/pr24/en/index.html Accessed April 7, 2009
38. Harries A.D., Zachariah R., and Lawn S.D. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 13 1 (2009) 6-16
39. In: WHO (Ed). Anti-tuberculosis drug resistance in the world, 4th report: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. 2008 edition (2008), World Health Organization, Geneva 1-142
40. Zignol M., Hosseini M.S., Wright A., et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 194 4 (2006) 479-485
41. Shah N.S., Wright A., Bai G.H., et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13 3 (2007) 380-387
42. Migliori G.B., Loddenkemper R., Blasi F., et al. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?. Eur Respir J 29 3 (2007) 423-427
43. Manissero D., and Fernandez de la Hoz K. Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: summary update. Euro Surveill 11 11 (2006) E061103.1
44. Raviglione M. XDR-TB: entering the post-antibiotic era?. Int J Tuberc Lung Dis 10 11 (2006) 1185-1187
45. Raviglione M.C., and Smith I.M. XDR tuberculosis-implications for global public health. N Engl J Med 356 7 (2007) 656-659
46. Corbett E.L., Charalambous S., Moloi V.M., et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 170 6 (2004) 673-679
47. Ottmani S.E., and Uplekar M.W. Gender and TB: pointers from routine records and reports. Int J Tuberc Lung Dis 12 7 (2008) 827-828
48. Thorson A., Long N.H., and Larsson L.O. Chest X-ray findings in relation to gender and symptoms: a study of patients with smear positive tuberculosis in Vietnam. Scand J Infect Dis 39 1 (2007) 33-37
49. Borgdorff M.W., Nagelkerke N.J., Dye C., et al. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis 4 2 (2000) 123-132
50. Connolly M., and Nunn P. Women and tuberculosis. World Health Stat Q 49 2 (1996) 115-119
51. Somma D., Thomas B.E., Karim F., et al. Gender and socio-cultural determinants of TB-related stigma in Bangladesh, India, Malawi and Colombia. Int J Tuberc Lung Dis 12 7 (2008) 856-866
52. Dye C., Garnett G.P., Sleeman K., et al. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 352 9144 (1998) 1886-1891
53. Dye C., Watt C.J., Bleed D.M., et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293 22 (2005) 2767-2775
54. Enarson D.A., Seita A., and Fujiwara P. Global elimination of tuberculosis: implementation, innovation, investigation. Int J Tuberc Lung Dis 7 12 Suppl 3 (2003) S328-S332
55. Lonnroth K., and Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 29 5 (2008) 481-491
56. Dye C., and Williams B.G. Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5 23 (2008) 653-662
57. Sterling T.R. New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med 29 5 (2008) 532-541
58. Woldehanna S., and Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 1 (2004) CD000171
59. Churchyard G.J., Scano F., Grant A.D., et al. Tuberculosis preventive therapy in the era of HIV infection: overview and research priorities. J Infect Dis 196 Suppl 1 (2007) S52-S62
60. Grimwade K., Sturm A.W., Nunn A.J., et al. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 19 2 (2005) 163-168
61. Bock N.N., Jensen P.A., Miller B., et al. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 196 Suppl 1 (2007) S108-S113
62. Wells C.D., Cegielski J.P., Nelson L.J., et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196 Suppl 1 (2007) S86-107
63. Hopewell P.C., Pai M., Maher D., et al. International standards for tuberculosis care. Lancet Infect Dis 6 11 (2006) 710-725
64. Lonnroth K., Uplekar M., Arora V.K., et al. Public-private mix for DOTS implementation: what makes it work?. Bull World Health Organ 82 8 (2004) 580-586
65. Ambe G., Lonnroth K., Dholakia Y., et al. Every provider counts: effect of a comprehensive public-private mix approach for TB control in a large metropolitan area in India. Int J Tuberc Lung Dis 9 5 (2005) 562-568
66. Lonnroth K., and Uplekar M. Invest in breaking the barriers of public-private collaboration for improved tuberculosis care. Bull World Health Organ 83 7 (2005) 558-559
67. Floyd K., Arora V.K., Murthy K.J., et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ 84 6 (2006) 437-445
68. Pantoja A., Floyd K., Unnikrishnan K.P., et al. Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients. Int J Tuberc Lung Dis 13 6 (2009) 698-704
69. Pai M., and O'Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 29 5 (2008) 560-568
70. Ly L.H., and McMurray D.N. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines 7 5 (2008) 635-650
71. Diacon A.H., Pym A., Grobusch M., et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360 23 (2009) 2397-2405
72. Nuermberger E., and Mitchison D.A. Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility. Am J Respir Crit Care Med 179 1 (2009) 2-3
73. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement. WHO. 2008. Available at: www.who.int/tb/features_archive/policy_statement.pdf. Accessed June 28, 2009.
74. Lonnroth K., Jaramillo E., Williams B.G., et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 68 12 (2009) 2240-2246
75. Squire S.B., Obasi A., and Nhlema-Simwaka B. The global plan to stop TB: a unique opportunity to address poverty and the Millennium Development Goals. Lancet 367 9514 (2006) 955-957